Fig. 2
From: Safety and immunogenicity of an HIV vaccine trial with DNA prime and replicating vaccinia boost
Humoral and cellular immune responses to HIV and vaccinia virus. a Response rates of anti-HIV gp120 IgG in DNA-L/rTV and DNA-H/rTV groups. b of Geometric mean titers (GMTs) of anti-HIV gp120 IgG in DNA-L/rTV and DNA-H/rTV groups, with error bars representing geometric standard deviations (GSD). c Response rates of anti-HIV gp120 IgG in vaccinia naïve and non-naïve subjects. d GMTs of anti-HIV gp120 IgG in vaccinia naïve and non-naïve subjects, with GSD error bars. e Response rates of anti-vaccinia virus IgG in vaccinia naïve and non-naïve subjects. f GMTs of anti-vaccinia virus IgG in vaccinia naïve and non-naïve subjects, with GSD error bars. g HIV-specific T cell responses rates of DNA-L/rTV and DNA-H/rTV groups. h HIV-specific T cell responses rates of vaccinia naïve and non-naïve subjects. ns: not significant (P > 0.05)
